Ironwood Pharmaceuticals (IRWD) Equity Average (2011 - 2026)

Ironwood Pharmaceuticals has disclosed Equity Average across 16 years of filings, most recently posting -$239.5 million for Q1 2026.

• Equity Average for Q1 2026 came in at -$239.5 million, up 24.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$239.5 million (up 24.62% YoY), and the FY2025 annual result was -$281.6 million, down 85.03% from the prior year.
• Equity Average came in at -$239.5 million for Q1 2026 at Ironwood Pharmaceuticals, up from -$263.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $679.6 million in Q1 2023 to a low of -$336.2 million in Q3 2023.
• The 5-year median for Equity Average is -$239.5 million (2026), against an average of $5.1 million.
• Across the five-year window, Equity Average surged 550.17% in 2022 and slumped 281.14% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Equity Average stood at $621.7 million in 2022, then plunged by 126.44% to -$164.4 million in 2023, then plunged by 86.39% to -$306.3 million in 2024, then increased by 14.15% to -$263.0 million in 2025, then increased by 8.94% to -$239.5 million in 2026.
• The last three Equity Average figures came in at -$239.5 million (Q1 2026), -$263.0 million (Q4 2025), and -$286.2 million (Q3 2025), per Business Quant data.